Medicalgorithmics Selected As Cardiac Safety Solutions Provider for International Clinical Trial
Medicalgorithmics, listed on the Warsaw Stock Exchange, has been selected by AnaCardio, a Swedish clinical-stage biopharmaceutical company, as a cardiac safety monitoring equipment provider in a clinical trial, conducted at leading clinical heart failure centers in the European Union and the United Kingdom. Approximately 80 heart failure patients will participate in the study with the use of the PocketECG 3 device. Medicalgorithmics is also in talks with potential partners on participating in further clinical trials in the US market, among others.